PharmEasy value crash may not hit Velumani’s stake
PharmEasy is faced with a steep cut in its valuation, with the new funding round pegging its shares at Rs 5 each compared to the Rs 50 per share that it secured in 2021. The huge fall in value has triggered questions about the fate of Velumani’s purchase of a 5% stake in the firm in 2021 when it was valued at $4 billion.
